Scholarlink

Introduction <p>This study aimed to determine the role of postoperative adjuvant therapy in patients with thymic carcinoma following complete resection.</p> Methods <p>We conducted a&#xa0;retrospective analysis of patients with stage&#xa0;I–III or N1+ thymic carcinomas who underwent complete resection at our center between 2006 and 2020. Data on the clinical characteristics and postoperative adjuvant therapies were collected.</p> Results <p>One hundred and twenty patients were enrolled. Five (4.2%) patients received only postoperative chemotherapy, 36&#xa0;(33.0%) received only postoperative radiotherapy, 75&#xa0;(62.5%) received postoperative chemoradiotherapy, and four (3.3%) did not receive any postoperative therapy. During a&#xa0;median follow-up period of 65&#xa0;months, disease failure was observed in 46&#xa0;(38.3%) patients, and 28&#xa0;(23.3%) patients died. The 5‑year disease-free survival (DFS) and overall survival (OS) rates were 58.7&#xa0;and 81.4%, respectively. Patients who underwent different postoperative therapies exhibited varying prognoses. Radiotherapy reduced the risks of failure (<i>p</i> &lt; 0.001) and death (<i>p</i> &lt; 0.001), whereas chemotherapy did not (<i>p</i> <i>=</i> 0.198 and 0.260 respectively). Subgroup analyses revealed that stage&#xa0;III/IV patients who received chemotherapy had a&#xa0;lower relapse risk (<i>p</i> <i>=</i> 0.045) and improved OS (<i>p</i> <i>=</i> 0.064). Multivariate analysis demonstrated that radiotherapy alone (hazard ratio [HR], 0.24; <i>p</i> = 0.023) independently predicted OS.</p> Conclusions <p>Adjuvant radiotherapy should be recommended for patients with thymic carcinoma who have undergone complete resection. Further exploration is needed to clarify the role of adjuvant chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月23日

查看全文
  • Yan Gao,
  • Xingwen Fan,
  • Hong Zheng,
  • Yingshan Cui,
  • Qiong Yi,
  • Yaqi Li,
  • Yulei Pei,
  • Kailiang Wu

摘要

Introduction

This study aimed to determine the role of postoperative adjuvant therapy in patients with thymic carcinoma following complete resection.

Methods

We conducted a retrospective analysis of patients with stage I–III or N1+ thymic carcinomas who underwent complete resection at our center between 2006 and 2020. Data on the clinical characteristics and postoperative adjuvant therapies were collected.

Results

One hundred and twenty patients were enrolled. Five (4.2%) patients received only postoperative chemotherapy, 36 (33.0%) received only postoperative radiotherapy, 75 (62.5%) received postoperative chemoradiotherapy, and four (3.3%) did not receive any postoperative therapy. During a median follow-up period of 65 months, disease failure was observed in 46 (38.3%) patients, and 28 (23.3%) patients died. The 5‑year disease-free survival (DFS) and overall survival (OS) rates were 58.7 and 81.4%, respectively. Patients who underwent different postoperative therapies exhibited varying prognoses. Radiotherapy reduced the risks of failure (p < 0.001) and death (p < 0.001), whereas chemotherapy did not (p = 0.198 and 0.260 respectively). Subgroup analyses revealed that stage III/IV patients who received chemotherapy had a lower relapse risk (p = 0.045) and improved OS (p = 0.064). Multivariate analysis demonstrated that radiotherapy alone (hazard ratio [HR], 0.24; p = 0.023) independently predicted OS.

Conclusions

Adjuvant radiotherapy should be recommended for patients with thymic carcinoma who have undergone complete resection. Further exploration is needed to clarify the role of adjuvant chemotherapy.